PROSPECTS OF NASAL ADMINISTRATION OF DRUGS IN THE PHARMACOTHERAPY OF ANXIETY DISORDERS
DOI:
https://doi.org/10.30888/2663-5712.2022-15-01-016Keywords:
anxiety disorders, pharmacotherapy, antidepressants, anxiolytics, nasal administration of drugsAbstract
The work examines a widespread group of psychological disorders, which for many years has maintained a tendency to further spread among the population, namely, anxiety disorders (TR). Therefore, improving the methods of pharmacotherapy of TR does not losMetrics
References
World Health Organization et al. Depression and other common mental disorders: global health estimates. – World Health Organization, 2017. – №. WHO/MSD/MER/2017.2.
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3. Epub 2022 Jan 10. PMID: 35026139; PMCID: PMC8776563.
Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, Wittchen HU. Anxiety disorders. Nat Rev Dis Primers. 2017 May 4;3:17024. doi: 10.1038/nrdp.2017.24. Erratum in: Nat Rev Dis Primers. 2017 Dec 14;3:17100. PMID: 28470168.
COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 6;398(10312):1700-1712. doi: 10.1016/S0140-6736(21)02143-7. Epub 2021 Oct 8. PMID: 34634250; PMCID: PMC8500697.
World Health Organization. ICD-11 for Mortality and Morbidity Statistics
Bosman RC, Ten Have M, de Graaf R, Muntingh AD, van Balkom AJ, Batelaan NM. Prevalence and course of subthreshold anxiety disorder in the general population: A three-year follow-up study. J Affect Disord. 2019 Mar 15;247:105-113. doi: 10.1016/j.jad.2019.01.018. Epub 2019 Jan 15. PMID: 30660019.
Strawn J. R. et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review //Expert opinion on pharmacotherapy. – 2018. – Т. 19. – №. 10. – С. 1057-1070.
Strawn J. R. et al. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis //Journal of the American Academy of Child & Adolescent Psychiatry. – 2018. – Т. 57. – №. 4. – С. 235-244. e2.
Jakubovski E. et al. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders //Depression and anxiety. – 2019. – Т. 36. – №. 3. – С. 198-212.
Gomez A. F., Barthel A. L., Hofmann S. G. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review //Expert opinion on pharmacotherapy. – 2018. – Т. 19. – №. 8. – С. 883-894.
Tafet G. E., Nemeroff C. B. Pharmacological treatment of anxiety disorders: the role of the HPA axis //Frontiers in psychiatry. – 2020. – Т. 11. – С. 443.
Costa C. et al. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis //Journal of Controlled Release. – 2019. – Т. 295. – С. 187-200.
Ramreddy S., Janapareddi K. Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation //Drug Development and Industrial Pharmacy. – 2019. – Т. 45. – №. 1. – С. 147-158.
Хохлов М.Б., Рубан О.А., Рубан Е.А. Сучасні аспекти інтраназального введення лікарських речовин у вигляді спреїв. – 2021.
Voncken M. J. et al. The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder //European Neuropsychopharmacology. – 2021. – Т. 53. – С. 25-33.
Mathé A. A. et al. A randomized controlled trial of intranasal neuropeptide y in patients with major depressive disorder //International Journal of Neuropsychopharmacology. – 2020. – Т. 23. – №. 12. – С. 783-790.
Musumeci T., Bonaccorso A., Puglisi G. Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview //Pharmaceutics. – 2019. – Т. 11. – №. 3. – С. 118.
Schrier L. et al. Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation //British journal of clinical pharmacology. – 2017. – Т. 83. – №. 4. – С. 721-731.
Черній В. І. и др. Порівняння ефективності аналгетичної дії назальної форми кеторолаку трометаміну «Asprix» та ін’єкційної форми кеторолаку трометаміну у післяопераційному періоді //Pain, anaesthesia & intensive care. – 2017. – №. 1 (78). – С. 44-53.
Хайтович М. В. Застосування назального інтерферону для профілактики та лікування гострої респіраторної вірусної інфекції. Національний медичний університет імені О.О. Богомольця
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
